

## Evidence for functional expression of TRPM7 channels in human atrial myocytes

Yan-Hui Zhang · Hai-Ying Sun · Kui-Hao Chen ·  
Xin-Ling Du · Bo Liu · Lik-Cheung Cheng ·  
Xin Li · Man-Wen Jin · Gui-Rong Li

Received: 14 December 2011 / Revised: 15 June 2012 / Accepted: 5 July 2012 / Published online: 18 July 2012  
© The Author(s) 2012. This article is published with open access at Springerlink.com

**Abstract** Transient receptor potential melastatin-7 (TRPM7) channels have been recently reported in human atrial fibroblasts and are believed to mediate fibrogenesis in human atrial fibrillation. The present study investigates whether TRPM7 channels are expressed in human atrial myocytes using whole-cell patch voltage-clamp, RT-PCR and Western blotting analysis. It was found that a gradually activated TRPM7-like current was recorded with a  $K^+$ - and  $Mg^{2+}$ -free pipette solution in human atrial myocytes. The current was enhanced by removing extracellular  $Ca^{2+}$  and  $Mg^{2+}$ , and the current increase could be inhibited by  $Ni^{2+}$  or  $Ba^{2+}$ . The TRPM7-like current was potentiated by acidic pH and inhibited by  $La^{3+}$  and 2-aminoethoxydiphenyl borate. In addition,  $Ca^{2+}$ -activated TRPM4-like current was recorded in human atrial myocytes with the addition of the

$Ca^{2+}$  ionophore A23187 in bath solution. RT-PCR and Western immunoblot analysis revealed that in addition to TRPM4, TRPM7 channel current, mRNA and protein expression were evident in human atrial myocytes. Interestingly, TRPM7 channel protein, but not TRPM4 channel protein, was significantly increased in human atrial specimens from the patients with atrial fibrillation. Our results demonstrate for the first time that functional TRPM7 channels are present in human atrial myocytes, and the channel expression is upregulated in the atria with atrial fibrillation.

**Keywords** Human atrial myocytes · TRPM7 channels · TRPM4 channels · Atrial fibrillation

Y.-H. Zhang · H.-Y. Sun · G.-R. Li  
Department of Medicine, Li Ka Shing Faculty of Medicine,  
The University of Hong Kong, Pokfulam, Hong Kong, China

K.-H. Chen · M.-W. Jin  
Department of Pharmacology, Tongji Medical College,  
Huazhong University of Science and Technology, Wuhan, China

X.-L. Du · B. Liu  
Department of Cardiac Surgery, Union Hospital, Tongji Medical  
College, Huazhong University of Science and Technology,  
Wuhan, China

L.-C. Cheng · X. Li  
Department of Surgery, Li Ka Shing Faculty of Medicine,  
The University of Hong Kong, Pokfulam, Hong Kong, China

G.-R. Li (✉)  
Department of Physiology, Li Ka Shing Faculty of Medicine,  
The University of Hong Kong, L4-59, Laboratory Block,  
21 Sassoon Road, Pokfulam, Hong Kong, China  
e-mail: grli@hku.hk

### Introduction

Recent progress in studies on transient receptor potential (TRP) channels has greatly improved our understanding of cellular physiology and pathophysiology in different mammalian systems. The superfamily of TRP channels comprises 28 cation-permeable channels expressed throughout the animal kingdom. They include seven sub-families based on their structure homology: TRPC (canonical), TRPV (vanilloid), TRPM (melastatin), TRPP (polycystin), TRPML (mucolipin), TRPA (ankyrin), and TRPN (no-mechanopotential) [3, 8]. TRP channels are expressed in most non-excitabile and excitabile tissues and involved in many fundamental cellular functions such as  $Ca^{2+}$  signaling, contraction, proliferation, and cell death [9, 38]. Several types of TRP channel genes have recently been described in the heart of different species. They include TRPC5 [4], TRPC6 [27], TRPM4 [15], TRPP1 and TRPP2 [6], in human cardiac tissue and/or myocytes; TRPC3/6,

TRPV2/4, TRPM3/7, and TRPP2 in mouse cardiac tissue and/or myocytes, and TRPC1/3, TRPC6, and TRPM4 in rat cardiac myocytes [24]. It was reported that mRNA and protein of TRPC1/3 channels were upregulated in human atrial tissue with atrial fibrillation and a goat model of atrial fibrillation [47]. A recent report showed that TRPC3 channels regulate rat cardiac fibroblast proliferation by controlling calcium entry [20].

Most studies on TRP channels in cardiac tissues from different species, however, only demonstrate the presence of genes and/or protein expression of these channels. The information regarding the current properties of the TRP channels in native human cardiac myocytes is scarce in published literature. Earlier studies reported single channel current of TRPM4 channels in mouse sino-atrial node cells [10], rat ventricular myocytes [16], and human atrial myocytes [15]. Gwanyanya and coworkers demonstrated that a  $Mg^{2+}$ -inhibited, TRPM6/7-like current was present in rat and pig ventricular myocytes [18, 19]. A recent study has demonstrated that TRPM7 channels are expressed in human atrial fibroblasts, which mediate  $Ca^{2+}$  signals and confer fibrogenesis in humans with atrial fibrillation [13]. It is unknown whether TRPM7 channels are present in human atrial myocytes. In the present study, we are interested in determining whether the functional TRPM7 channels are expressed in human atrial myocytes with whole-cell patch voltage-clamp, RT-PCR, and Western immunoblotting analysis.

## Materials and Methods

### Human atrial myocyte preparation

Atrial myocytes were enzymatically isolated from specimens of human right atrial appendage obtained from patients undergoing coronary artery bypass grafting, valve repair or replacement, and the patient information is shown in Table 1. The experimental procedure for obtaining the human atrial tissue was approved by the Ethics Committee of the University of Hong Kong (UW-10-174) based on the patients' consent. The human cardiac cell isolation procedure was adopted as described previously [31, 32]. The isolated human atrial myocytes were used for whole-cell patch voltage-clamp recording of membrane current and identifying gene expression of TRPM channels.

### Solution and chemicals

Tyrode solution contained (mM) NaCl 140.0, CsCl 5.0,  $MgCl_2$  1.0,  $CaCl_2$  1.8, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 10.0 and glucose 10.0 (pH adjusted to 7.3 with NaOH). Divalent-free solution

**Table 1** Characteristics of the patients

	Sinus rhythm	Atrial fibrillation
<i>n</i> (m/f)	38 (25/13)	22 (15/7)
Age (years old)	55 ± 3.2	57 ± 4.6
CAD ( <i>n</i> )	33	3
MVD ( <i>n</i> )	4	18
AVD/MVD ( <i>n</i> )	1	1
Hypertension ( <i>n</i> )	15	4
LVEF (%)	61.7 ± 2.3	57.2 ± 2.1
LA (mm)	36.2 ± 1.2	49.7 ± 1.5
Medication ( <i>n</i> )		
Digitalis	3	10
ACE inhibitors	14	5
$\beta$ -blockers	20	2
Calcium channel blockers	11	4
Diuretics	10	14
Nitrates	9	2

CAD coronary artery disease, MVD mitral valve disease, AVD aorta valve disease, LVEF left ventricular ejection factor, LA left atrial size, ACE angiotensin-converting-enzyme

was prepared by simply omitting the  $CaCl_2$  and  $MgCl_2$  from the standard solution. Nifedipine (3  $\mu$ M) was included in the extracellular solutions to block L-type  $Ca^{2+}$  channels.  $Na^+$ -free external solution was prepared by substituting NaCl with *N*-methyl-D-glucamine-chloride (NMDG-Cl) when external solutions used to study cation permeability contained 10 mM of  $Na^+$ ,  $K^+$ ,  $Mg^{2+}$  or  $Ca^{2+}$ , added to the NMDG-Cl solution. The  $Mg^{2+}$ -free pipette solution (for recording TRPM7 current) contained (mM) Cs-aspartate 110.0, CsCl 20.0, Na-phosphocreatine 5.0, HEPES 10.0, Cs-EGTA 5.0, GTP 0.1, and Na-ATP 5.0, pH adjusted to 7.2 with CsOH. The pipette solution (for recording TRPM4 current) contained (mM): Cs-aspartate 110.0, CsCl 20.0,  $MgCl_2$  1.0, Na-phosphocreatine 5.0, HEPES 10.0, Cs-EGTA 0.05, GTP 0.1, and Mg-ATP 5.0, pH adjusted to 7.2 with CsOH.

All chemicals were purchased from Sigma-Aldrich Chemicals (St Louis, MO, USA). Stock solutions were made with dimethyl sulfoxide (DMSO) for 2-aminooxydiphenyl borate (2-APB, 100 mM), A23187 (10 mM). The stocks were divided into aliquots and stored at  $-20^\circ C$ .  $LaCl_3$  stock solution (100 mM) was made with distilled water.

### Electrophysiology

A small aliquot of the solution containing the isolated human atrial myocytes was placed in an open perfusion chamber (0.5 ml) mounted on the stage of an inverted microscope (Diaphot, Nikon, Japan). Myocytes were

allowed to adhere to the bottom of the chamber for 10–20 min and superfused at  $\sim 2$  ml/min with Tyrode solution. Only quiescent rod-shaped cells with clear cross-striations were used for electrophysiological recording.

Whole-cell currents were recorded as described previously [31, 32]. Borosilicate glass electrodes (1.2-mm OD) were pulled with a Brown-Flaming puller (model P-97, Sutter Instrument Co, Novato, CA, USA) and had tip resistances of 1.5–3 M $\Omega$  when filled with the pipette solution. A 3 M KCl-Agar bridge was used as the reference electrode. The tip potential was zeroed before the patch pipette contacted the cell. After a gigaohm seal was obtained by negative pressure, the cell membrane was ruptured by applying a gentle negative pressure to establish the whole-cell configuration. Series resistance (3–6 M $\Omega$ ) was compensated by 50–80% to minimize voltage errors. Junction potentials (calculated 15.7 mV) between pipette and bath solutions were not corrected for the patch clamp recording. Membrane currents were measured using an EPC-10 amplifier and Pulse software (Heka Elektronik, Lambrecht, Germany). Command pulses were generated by a 12-bit digital-to-analog converter controlled by Pulse software. The obtained data were stored on an IBM PC computer for offline data analysis. All experiments were conducted at room temperature (22–23 °C).

#### Reverse transcript polymerase chain reaction

The reverse transcript polymerase chain reaction (RT-PCR) was performed with a procedure described previously [30]. Briefly, the total RNA was isolated using the TRIzol method (Invitrogen) from human atrial myocytes then treated with DNase I (Promega, Madison, WI, USA). Reverse transcription (RT) was performed with RT system (Promega, Madison, WI, USA) protocol in 20  $\mu$ l reaction mixtures. RNA (1  $\mu$ g) was used in the reaction, and a combination of oligo (dT) and random hexamer promoters was used for the initiation of cDNA synthesis. After RT, the reaction mixture (cDNA) was used for polymerase chain reaction (PCR). The forward and reverse PCR oligonucleotide primers chosen to amplify the cDNA are listed in Table 1. PCR was performed by a Promega PCR system with *Taq* polymerase and accompanying buffers. The cDNA in 2  $\mu$ l aliquots was amplified by a DNA thermal cycler (MyCycler; Bio-Rad, Hercules, CA, USA) in a 25  $\mu$ l reaction mixture containing 1.0 thermophilic DNA polymerase reaction buffer, 1.25 mM MgCl<sub>2</sub>, 0.2 mM each deoxynucleotide triphosphate (dNTP), 0.6  $\mu$ M of each forward and reverse primer, and 1.0 U of *Taq* polymerase under the following conditions: the mixture was annealed at 50–60 °C (1 min), extended at 72 °C (2 min), and denatured at 95 °C (45 s) for 30 cycles. This was followed by a final extension at 72 °C (10 min) to ensure complete

product extension. The PCR products were electrophoresed through a 1.5% agarose gel, and the amplified cDNA bands were visualized by ethidium bromide staining. The bands were imaged by Chemi-Genius Bio-Imaging System (Syngene, Cambridge, UK).

#### Western immunoblotting analysis

The related ion channel proteins were determined with Western immunoblotting analysis [22, 46]. The specimens of human right atrial appendage obtained from patients undergoing coronary artery bypass grafting or valve repair were frozen and stored at  $-80$  °C. For Western immunoblotting analysis, the specimens were homogenized in ice-cold modified RIPA lysis buffer (50 mM Tris-Cl, pH 8, 150 mM NaCl, 1% Nonidet P-40 (NP-40), 0.5% sodium deoxycholate, 1% SDS) with a small tissue-mincer then sonicated to promote lysis. The samples were then centrifuged at 13,000 rpm at 4 °C for 30 min. The supernatants were collected, and protein concentration was determined with Bio-Rad protein assay. Lysates containing equal amounts of protein were mixed with SDS sample buffer and denatured at 95 °C for 5 min. Samples were electrophoresed on SDS-PAGE gels, and transferred onto nitrocellulose membranes. Subsequently, membranes were blocked with 5% non-fat dried milk (Bio-Rad) in TTBS (0.1% Tween-20) for 1 h at RT and incubated overnight at 4 °C with primary antibodies (mouse monoclonal anti-TRPM7, NeuroMab, USA; goat polyclonal anti-TRPM4, Santa Cruz Biotechnology, Inc.; goat polyclonal anti-GAPDH, Santa Cruz Biotechnology). The membranes were treated with goat anti-mouse or donkey anti-goat IgG-HRP antibody (1:5000, Santa Cruz Biotechnology) for 1 h at room temperature. Blots were developed with enhanced chemiluminescence (ECL, GE Healthcare, Hong Kong) and exposed on X-ray film (Fuji Photo Film GmbH). The film was scanned, imaged by a Bio-Imaging System (Syngene, Cambridge, UK), and analyzed via Gene Tools software (Syngene).

#### Immunocytochemistry

Isolated human atrial myocytes were washed with IMDM medium (Sigma-Aldrich) and seeded on coverslips pre-coated with Laminin. After 4–8 h adhering, the cells were washed with PBS, and fixed with PBS containing 2% paraformaldehyde (PFA) for 20 min, and subsequently permeabilized with PBS containing 0.1% Triton X-100 for 3 min. The cells were incubated with blocking buffer (5% BSA in PBS) for 1 h after washing three times with PBS. The cells were incubated at 4 °C overnight with a primary antibody diluted in PBS containing 3% BSA, washed with PBS, and incubated with the fluorescence-labeled secondary antibody (Invitrogen) in PBS with 3% BSA in the dark

at room temperature for 1 h. The coverslip was then washed four times with PBS and mounted with ProLong Gold Anti-fade Reagent (Invitrogen, Hong Kong, China) for durable visualization. The coverslip was then observed and captured with confocal microscopy (Olympus FV300, Tokyo, Japan).

### Statistical analysis


The data are expressed as mean  $\pm$  SEM. Paired and/or unpaired Student's *t* test were used as appropriate to evaluate the statistical significance of differences between two group means; ANOVA was used for multiple groups. Values of  $P < 0.05$  were considered to be statistically significant.

## Results

### TRPM7-like current in human atrial myocytes

A previous report by Gwanyanya and colleagues demonstrated a TRPM6/7-like cation current in rat and pig ventricular myocytes [18] when a  $Mg^{2+}$ -free pipette solution was used to record the membrane current. In this study, we used a modified  $K^+$ - and  $Mg^{2+}$ -free pipette solution to investigate whether TRPM7-like current is present in cardiac myocytes isolated from human atrial specimens.


Figure 1a illustrates the whole-cell current recorded with a 3-s voltage ramp from  $-100$  to  $+80$  mV from a holding potential of  $-40$  mV in a representative human atrial myocyte. The membrane conductance gradually increased with the time of dialysis of the  $Mg^{2+}$ -free pipette solution, and reached a steady-state level at 30–60 min after cell membrane rupture. Current–voltage (*I*–*V*) relationships were changed from linear to outward rectification with the  $Mg^{2+}$ -free dialysis. Voltage-dependent current elicited with 300 ms voltage steps between  $-120$  and  $+80$  mV from a holding potential of  $-40$  mV (Fig. 1b) also exhibited an outward rectification. The step current showed rapid activation and outward rectification without inactivation as that described in HEK 293 cells stably expressing TRPM7 gene [25]. The increase of membrane conductance was observed in all the cells with  $Mg^{2+}$ -free dialysis, suggesting that TRPM7-like current is widely present in human atrial myocytes. The mean values of membrane current ( $+80$  mV) at different time points of  $Mg^{2+}$ -free dialysis are illustrated in Fig. 1c. The membrane current density was significantly increased at 10-min dialysis and the steady-state level of the current was seen at 30–60 min dialysis ( $n = 17$ ,  $P < 0.05$  or  $P < 0.01$  vs. 1 min dialysis).



**Fig. 1** TRPM7-like current in human atrial myocytes. **a** Time course of membrane current recorded in a representative human myocyte with a  $K^+$  and  $Mg^{2+}$ -free pipette solution using a 3-s ramp from  $-100$  to  $+80$  mV from a holding potential of  $-40$  mV. Original ramp *I*–*V* currents at corresponding time points are shown in *right side* of the panel. **b** Voltage-dependent current traces recorded with 300-ms steps between  $-120$  and  $+80$  mV from a holding potential of  $-40$  mV at 1, 10, 20, 30, 40, and 60 min after membrane rupture. **c** Mean values of the current at  $+80$  mV at different time points of  $Mg^{2+}$ -free dialysis ( $n = 17$ , \* $P < 0.05$ , \*\* $P < 0.01$  vs. 1 min)

Figure 2 displays that the removal of extracellular physiological divalent ions, e.g. bath  $Mg^{2+}$  and  $Ca^{2+}$ , reversibly enhanced outward current and inward current (Fig. 2a), and application of 2 mM  $Ni^{2+}$  (Fig. 2b) or 2 mM  $Ba^{2+}$  (data not shown) inhibited the enhanced currents induced by removing extracellular  $Ca^{2+}$  and  $Mg^{2+}$ . These properties are similar to those observed in pig and rat ventricular myocytes [18], suggesting that the current is likely mediated by TRPM7-like channels in human atrial myocytes.

To examine ionic permeability of the TRPM7-like channels, physiological ions  $Na^+$ ,  $K^+$ ,  $Ca^{2+}$ , and  $Mg^{2+}$  were applied at equimolar concentrations (10 mM) in  $Na^+$ -free bath solution ( $Na^+$  was replaced by organic monovalent cation NMDG $^+$ ) to examine their permeability through




**Fig. 2** Enhancement of inward and outward currents by removing bath  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$ . **a** Time course of membrane current recorded in a typical experiment with the ramp protocol used in Fig. 1a with a  $\text{K}^{+}$ - and  $\text{Mg}^{2+}$ -free pipette solution. Removal of bath  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$  ( $\text{Ca}_0^{2+}$ - $\text{Mg}_0^{2+}$ -free) induced a remarkable increase of inward and outward currents. Original ramp  $I$ - $V$  currents at corresponding time points are shown in right side of the panel. **b** Time course of membrane current recorded in another typical experiment with the ramp protocol used in Fig. 1a. The increased current induced by removing bath  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$  ( $\text{Ca}_0^{2+}$ - $\text{Mg}_0^{2+}$ -free) was inhibited by 2 mM  $\text{Ni}^{2+}$ . Original ramp  $I$ - $V$  currents at corresponding time points are shown in right side of the panel

the TRPM7-like channels in human atrial myocytes. Figure 3 shows the ionic permeability of  $\text{Na}^{+}$ ,  $\text{K}^{+}$ ,  $\text{Ca}^{2+}$ , and  $\text{Mg}^{2+}$ . A large inward current was induced by 10 mM  $\text{K}^{+}$  and small inward current was induced by 10 mM  $\text{Na}^{+}$ .  $\text{Ca}^{2+}$  or  $\text{Mg}^{2+}$  caused a small increase of inward current and significant inhibition of outward current (Fig. 3a, b). The mean permeability of physiological ions is illustrated in Fig. 3c. The  $\text{K}^{+}$  permeability was high, while the permeability to  $\text{Na}^{+}$ ,  $\text{Mg}^{2+}$ , and  $\text{Ca}^{2+}$  was 0.10, 0.24, and 0.17 of  $\text{K}^{+}$ , respectively. These results suggest that TRPM7-like channels are highly permeable to  $\text{K}^{+}$  in human atrial myocytes.

Molecular identity of TRPM7-like current in human atrial myocytes


The molecular identity of TRPM7-like channels was determined with RT-PCR and Western immunoblot



**Fig. 3** Permeability of TRPM7-like channels to physiological cations. **a** Time course of membrane inward current recorded in a representative cell with the ramp protocol used in Fig. 1a using a cation-free (NMDG) bath solution with application of equimolar (10 mM)  $\text{Na}^{+}$ ,  $\text{K}^{+}$ ,  $\text{Mg}^{2+}$ , and  $\text{Ca}^{2+}$ , respectively. **b** The original ramp inward currents in panel A with application of equimolar (10 mM)  $\text{Na}^{+}$ ,  $\text{K}^{+}$ ,  $\text{Mg}^{2+}$ , and  $\text{Ca}^{2+}$ , respectively. **c** Mean relative permeability of TRPM7-like channels to  $\text{K}^{+}$ ,  $\text{Na}^{+}$ ,  $\text{Mg}^{2+}$ , and  $\text{Ca}^{2+}$  ( $n = 5$ – $6$ ) in human atrial myocytes

analysis. Figure 4a shows the results of RT-PCR using the primers designed for the human genes TRPM1, TRPM2, TRPM3, TRPM4, TRPM5, TRPM6, TRPM7, TRPM8, and GAPDH as shown in Table 2. The gene expression of TRPM4, TRPM7, and GAPDH was evident in human atrial myocytes. The expression of TRPM4 channels is consistent with the previous observation in human atrial myocytes [15]. RT-PCR showed that TRPM7 channel gene was also expressed in human atrial myocytes.

Figure 4b shows the Western immunoblots of TRPM4 and TRPM7 proteins in human atrial specimens from four patients with sinus rhythm using anti-TRPM4 and anti-TRPM7 antibodies, respectively. The proteins of TRPM4 and TRPM7 channels were abundant in all human atrial tissues. Figure 4c illustrates the immunostaining of TRPM4 and TRPM7 expression in the surface of human atrial myocytes. These results confirm the expression of TRPM4 and TRPM7 channels in human atria, and the  $\text{Mg}^{2+}$ -sensitive current observed above is mediated by TRPM7 channels.



**Fig. 4** Gene and protein expression of TRPM channels in human atrial myocytes. **a** RT-PCR images for human TRPM channel genes. **b** Western immunoblots of TRPM4 and TRPM7 in human atrial tissues from four patients with sinus rhythm. **c** Immunostaining of TRPM4 and TRPM7 channels with anti-TRPM4 and anti-TRPM7 antibodies in human atrial myocytes

#### Effect of acidic pH on TRPM7 current in human atrial myocytes

Bath solution with acidic pH potentiated inward current in HEK 293 cells expressing TRPM7 and/or TRPM6 channels [33]. To examine how TRPM7 current in human atrial myocytes is affected by acidic bath pH, the membrane current was recorded by a 3-s ramp from  $-100$  to  $+80$  mV from a holding potential of  $-40$  mV by altering bath pH from 7.3 to 6.0, 5.0, or 4.0 (Fig. 5). It is interesting to note that bath pH at 5.0 or 4.0 reversibly increased both inward and outward currents of TRPM7 in human atrial myocytes (Fig. 5a). The mean values of current alteration are illustrated in Fig. 5b. The current was not altered at pH 6.0, and significant potentiation of the current was observed when bath pH was lowered to 5.0 or 4.0 from 7.3. These results indicate that the sensitivity of TRPM7 in human atrial myocytes is similar, but not identical, to that observed in HEK 293 cells expressing TRPM7 and/or TRPM6 channels [33].

#### Blockade of TRPM7 current by $\text{La}^{3+}$ and 2-APB

Figure 6 shows the effects of the non-specific TRPM7 channel blockers  $\text{La}^{3+}$  and 2-APB [5, 21, 33] on TRPM7 current in human atrial myocytes. The time course of TRPM7 current (Fig. 6a) recorded in a typical experiment with a 3-s ramp protocol ( $-100$  to  $+80$  mV from  $-40$  mV) shows that the current was gradually increased by dialysis, and inhibited by  $\text{La}^{3+}$  at 10, 30 and 100  $\mu\text{M}$ .  $\text{IC}_{50}$  (concentration for 50% inhibition) of  $\text{La}^{3+}$  for inhibiting TRPM7 current at  $+80$  mV was 37.0  $\mu\text{M}$  (Fig. 6c). Figure 6b displays the time course of TRPM7 current in another representative cell. 2-APB at 30 and 100  $\mu\text{M}$  also reduced both inward and outward currents, and the reduction was partially reversed by washout. The  $\text{IC}_{50}$  of 2-APB for inhibiting TRPM7 current at  $+80$  mV was 34.1  $\mu\text{M}$ . These results indicate that both  $\text{La}^{3+}$  and 2-APB blocked TRPM7 current in human atrial myocytes like in other cell types [5, 21, 33].


#### Whole-cell current of TRPM4 channels in human atrial myocytes

A previous report characterized a single channel current of TRPM4, a  $\text{Ca}^{2+}$ -activated non-selective cationic channel, in human atrial myocytes [15]. To demonstrate whole-cell current of TRPM4 channels in human atrial myocytes, we used a pipette solution with low EGTA (0.05 mM) to record membrane current with 500-ms voltage steps between  $-100$  and  $+90$  mV from a holding potential of  $-40$  mV, and then back to  $-100$  mV. Because TRPM4 channels are activated by intracellular free  $\text{Ca}^{2+}$  [15, 39], the  $\text{Ca}^{2+}$  ionophore A23187 [2] was used to activate the current. Figure 7a shows the voltage-dependent current traces in a representative myocyte before and after application of 10  $\mu\text{M}$  A23187 to the bath solution. The time-dependent current with a large inward tail current at  $-100$  mV, typical of TRPM4 current [39] was activated by application of A23187 for about 5 min. Similar results were obtained in four out of six myocytes treated with A23187.

In another group of experiments, we tested whether the TRPM4 inhibitor flufenamic acid [10] could inhibit the current. Figure 7b shows the  $I$ - $V$  relationships of membrane current recorded in a typical experiment with a 3-s ramp protocol from  $-100$  to  $+90$  mV in the absence and presence of 10  $\mu\text{M}$  A23187, and A23187 plus 10  $\mu\text{M}$  flufenamic acid. A23187-activated current was significantly inhibited by flufenamic acid. In a total 12 myocytes, A23187 increased the membrane conductance in seven cells, and the increased current was antagonized by flufenamic acid (Fig. 7c,  $n = 7$ ,  $P < 0.01$  vs. A23187 alone).

**Table 2** Human gene-specific primers for RT-PCR

Gene (accession no.)	Primer sequences (5'–3')	Fragment size (bp)
GAPDH (J_02642)	Forward AACAGCGACACCCACTCCTC Reverse GAGGGGAGATTTCAGTGTGGT	258
hTRPM1 (NM_002420)	Forward TTTCGGACCCTTTACAAC Reverse TCTGCTCGTCATGCTTAT	421
hTRPM2 (NM_003307)	Forward ACGGACCAGATTTGGAAGTT Reverse ATGGCGTCAACCTTATTGC	299
hTRPM3 (NM_024971)	Forward TCATTATGCTGGTGGTTC Reverse AATATCATGGTCATGTGGC	436
hTRPM4 (NM_017636)	Forward GCGGAGACCCTGGAAGACA Reverse CCAAGCCACAGCCAAACG	277
hTRPM5 (NM_014555)	Forward CTGGACGAGATTGATGAAGCC Reverse ACGAGACCCGAGCAGTAGTT	581
hTRPM6 (NM_017662)	Forward GACAACAGGAGCGTGGAT Reverse CAGGATGAAGTGCAGTGC	247
hTRPM7 (NM_017672)	Forward AAGCATTAGTTGCCTGTA Reverse GCATCTTGAGATTGTGGG	421
hTRPM8 (NM_024080)	Forward TGCCATCTCCTACGCTCTA Reverse TTCGAACCAGTTTCCAG	372




**Fig. 5** Effect of acidic bath pH on TRPM7 current in human atrial myocytes. **a** TRPM7 current recorded with the ramp protocol used in Fig. 1a at bath pH 7.3 and 5.0 (left panel), and pH 7.3 and 4.0 (right panel). **b** Normalized currents at  $-100$  and  $+80$  mV at different pH ( $n = 5$ ,  $*P < 0.05$ ,  $**P < 0.01$  vs. pH 7.3)

These results indicate that TRPM4 current is present in human atrial myocytes.

TRPM4 and TRPM7 expression in human atria from patients with atrial fibrillation

We finally determined whether TRPM4 and TRPM7 channel protein expression would be altered in atria from patients with atrial fibrillation. Figure 8a shows the Western immunoblot detection of TRPM4 and TRPM7 in atrial protein samples from three patients with sinus rhythm and three patients with atrial fibrillation. No significant change was observed in TRPM4 protein, while remarkable increase was observed in TRPM7 protein in the three atrial samples from patients with atrial fibrillation. Figure 8b displays the mean percentage values of TRPM4 and TRPM7 protein expression in the atria with sinus rhythm ( $n = 12$ ) and the atria with atrial fibrillation ( $n = 12$ ). TRPM7 channel protein expression was increased by  $71.5 \pm 12.8\%$  in atria of patients with atrial fibrillation ( $P < 0.01$  vs. sinus rhythm), while no change was seen for TRPM4 channel protein expression in atria of patients with atrial fibrillation ( $P = \text{NS}$ ).

To examine whether TRPM7 current is upregulated in human atrial myocytes with atrial fibrillation,  $\text{Mg}_i^{2+}$ -sensitive current was analyzed in sinus rhythm myocytes and atrial fibrillation myocytes. Figure 8c illustrates the mean values of  $\text{Mg}_i^{2+}$ -sensitive TRPM7 current at  $-100$




**Fig. 6** Blockade of TRPM7 current by  $\text{La}^{3+}$  or 2-APB. **a** Time course of membrane current recorded in a representative cell with  $\text{K}^+$ - and  $\text{Mg}^{2+}$ -free pipette solution using the ramp protocol used in Fig. 1a in the absence and presence of 10, 30, and 100  $\mu\text{M}$   $\text{La}^{3+}$ . Original  $I$ - $V$  traces at corresponding time points are shown in right side of the panel. **b** Time course of membrane current recorded in another typical experiment using the ramp protocol used in Fig. 1a in the absence and presence of 30 and 100  $\mu\text{M}$  2-APB. Original  $I$ - $V$  traces at corresponding time points are shown in right side of the panel. **c** Concentration-dependent curve of  $\text{La}^{3+}$  for inhibiting the current at +80 mV was fitted to a Hill equation. **d** Concentration-dependent curve of 2-APB for inhibiting the current at +80 mV was fitted to the Hill equation

and +80 mV at 30 min  $\text{Mg}^{2+}$ -free dialysis in human atrial myocytes without or with atrial fibrillation. The density of  $\text{Mg}_i^{2+}$ -sensitive TRPM7 current was greater in myocytes with atrial fibrillation than that in cells with sinus rhythm. This indicates an increase of TRPM7 current in human atrial fibrillation.

## Discussion

The present study demonstrates that both TRPM4 channels and TRPM7 channels are present in human atrial myocytes. TRPM7 current is gradually activated by dialysis with a  $\text{Mg}^{2+}$ -free pipette solution, enhanced by removing bath divalent cations, and potentiated by acidic pH. TRPM7 channels are preferentially permeable to  $\text{K}^+$ , and less permeable to equimolar (10 mM)  $\text{Na}^+$ ,  $\text{Mg}^{2+}$  and  $\text{Ca}^{2+}$ .




**Fig. 7** TRPM4 current in human atrial myocytes. **a** Voltage-dependent currents recorded in a typical experiment with 500-ms voltage steps between  $-100$  to  $+90$  mV from a holding potential of  $-40$  mV before and after application of 10  $\mu\text{M}$  A23187 (5 min). **b** Ramp  $I$ - $V$  traces recorded in a typical experiments in the absence and presence of 10  $\mu\text{M}$  A23187, and A23187 plus 10  $\mu\text{M}$  flufenamic acid. **c** Mean values of the current measured at  $-100$  and  $+90$  mV before (control) and after 10  $\mu\text{M}$  A23187 application, and A23187 plus 10  $\mu\text{M}$  flufenamic acid ( $n = 7$ ,  $**P < 0.01$  vs. control;  $##P < 0.01$  vs. A23187 alone)

TRPM7 current is inhibited by  $\text{La}^{3+}$  and 2-APB. Whole-cell current of TRPM4 channels is activated by the  $\text{Ca}^{2+}$  ionophore A23187 in human atrial myocytes. Molecular identities of TRPM4 and TRPM7 channels are confirmed by RT-PCR, Western blot, and immunocytochemistry. Interestingly, TRPM7, but not TRPM4, is markedly upregulated in human atria from patients with atrial fibrillation.

More than ten TRP channels have been demonstrated to be expressed in the heart and vasculature of mammals including humans [23, 50]. They include TRPC1, 2, 3, 4, 6,





**Fig. 8** Alteration of TRPM channel protein expression in human atria from patients with atrial fibrillation (AF). **a** Western immunoblots of TRPM4 and TRPM7 in atria samples from patients with sinus rhythm ( $n = 3$ ) or atrial fibrillation ( $n = 3$ ). **b** Mean percentage values of relative expression of TRPM4 and TRPM7 channels in human atria from patients with sinus rhythm (SR) and atrial fibrillation ( $n = 12$  patients for each group,  $**P < 0.01$  vs. sinus rhythm). **c** Mean values of  $Mg^{2+}$ -free sensitive TRPM7 current obtained by digital subtraction of the current recorded at 30 min by the current recorded at 1 min of dialysis ( $n = 14$  experiments from three AF patients,  $*P < 0.05$ ,  $** < 0.01$  vs. SR cells,  $n = 18$  experiments from five SR patients)

and 7 channels in mouse sinoatrial node and/or myocytes [26], TRPC3/6, TRPV2, 4, TRPM3, 7, and TRPP2 channels in mouse cardiac tissue and/or myocytes and TRPC1, 3, and TRPC6 channels in rat cardiac myocytes [24], TRPC5 channels in human cardiac hypertrophic ventricle [4], TRPM4 channels in mouse sinus node cells [10], rat ventricular myocytes [17], and human atrial myocytes [15]. A recent study demonstrated that TRPC1, 4, 6, TRPV2, 4, and TRPM4, 7 channels are expressed in human atrial fibroblasts [13]. Although the molecular identity has not been confirmed, TRPM6/7-like channel current was described in rat and pig ventricular myocytes [18, 19]. The

present study provides the novel information that in addition to TRPM4 channels, functional TRPM7 channels are expressed in human atrial myocytes.

TRPM7 (ChaK1, TRP-PLIK, LTRPC7) is a ubiquitous, calcium-permeant ion channel that is unique in being both an ion channel and a serine/threonine kinase regulated by intracellular ATP and phosphatidylinositol 4,5-bisphosphate ( $PIP_2$ ) [36, 43, 44]. The current is characterized by gradual activation during dialysis with  $Mg^{2+}$ -free pipette solution, and is potentiated by removing bath divalent ions, increased by acidic pH, and inhibited by 2-APB and/or  $La^{3+}$  (or  $Gd^{3+}$ ) [13, 25, 33, 43].

In human atrial myocytes, as well as in pig and rat ventricular myocytes [18], the TRPM7 current was gradually activated by dialysis with  $Mg^{2+}$ -free pipette solution. The inward and outward currents were potentiated by removing bath  $Ca^{2+}$  and  $Mg^{2+}$ , and the potentiation effect was inhibited by  $Ni^{2+}$  or  $Ba^{2+}$ . TRPM7 channels in human atrial myocytes are permeable to  $K^+$ ,  $Na^+$ ,  $Mg^{2+}$ , and  $Ca^{2+}$ , similar to the TRPM7 channels expressed in CHO cells [43]. Interestingly, TRPM7 current in human atrial myocytes was increased by acidic bath pH, similar to TRPM7 channels expressed in HEK 293 cells or TRPM7-like current in human atrial fibroblasts [13, 25, 33]. However, the response to bath pH is different from the TRPM6/7-like current observed in pig and rat ventricular myocytes, which was reduced by acidic bath pH [18]. It is unclear why the response of TRPM7 current in human atrial myocytes to acidic bath pH is opposite to the TRPM6/7-like current observed in pig and rat ventricular myocytes.

In addition, TRPM7 current in human atrial myocytes was inhibited by  $La^{3+}$  and 2-APB. The  $IC_{50}$  (34.1  $\mu M$ ) of 2-APB for inhibiting the current is close to that for inhibiting TRPM7 current in human atrial fibroblasts [13]. All properties described above support the notion that TRPM7 channels are expressed in human atrial myocytes. Moreover, the abundant expression of mRNA and protein further confirms the presence of TRPM7 channels in human atrial myocytes. However, the abundant protein of TRPM7 was measured in human atrial tissue, which could also be related to fibroblasts.

The upregulation of TRP channels is believed to mediate the progression of electrical remodeling and the arrhythmogenesis of the diseased heart [24]. TRPC3 expression is up-regulated in multiple rodent pathological cardiac hypertrophy models [4, 42]. TRPC-derived accumulation of intracellular  $Ca^{2+}$  is believed to contribute to selective activation of calcineurin in diseased heart [4]. Single channel activity and mRNA expression of  $Ca^{2+}$ -activated TRPM4 channels were upregulated in ventricular myocytes of spontaneously hypertensive rats, and believed to be the cause of the delayed-after-depolarizations observed during intracellular  $Ca^{2+}$  overload of

cardiomyocytes [17]. The present evidence for TRPM4 is consistent with previous observation for  $\text{Ca}^{2+}$ -activated TRPM4 channels in human atrial myocytes [15]. However, it is unknown whether there is any potential contribution of TRPM4 channels to atrial fibrillation since no change in channel protein expression was observed in atrial tissues from patients with atrial fibrillation.

One of limitations of the present study was that the current was recorded with  $\text{Cs}^+$  to block potassium channels, and nifedipine to block calcium channels, but not 4,4'-Diisothiocyano-2,2'-stilbenedisulfonic acid (DIDS) to block chloride channels, and the current may be contaminated by chloride current, especially when the  $\text{Ca}^{2+}$  ionophore A23187 [2] was used to activate TRPM4 channels. Our earlier studies demonstrated that only volume-sensitive chloride current was recorded with hypotonic (0.6 T) insult, and no evidence for cAMP/protein kinase A-regulated chloride current or  $\text{Ca}^{2+}$ -activated chloride current was observed in human atrial myocytes [28, 29]. Therefore, the potential contamination of the TRP current by chloride current would be very limited under physiological isotonic conditions in human atrial myocytes. On the other hand, there is no selective chloride channel blocker commercially available. The chloride channel blocker DIDS may also block TRPM4 channels [35].

Another limitation is that the atrial specimens were collected from a relative young patient population in the present study and only four patients with mitral valve disease in sinus rhythm group. The previous study established that valvular heart disease extensively remodels cardiac ion channel and transporter expression [14]. Nonetheless, the difference in patient age and heart disease would not affect the main outcome of the present study for demonstrating the evidence of TRPM7 channels in human atrial myocytes.

TRPM7 is a  $\text{Ca}^{2+}$  permeable channel, which is constitutively activated and brings  $\text{Ca}^{2+}$  into cells under physiological conditions [36, 43]. Although a previous study reported a TRPM6/7-like current in pig and rat ventricular myocytes and the presence of TRPM7 channels was demonstrated in human atrial myocytes in this study, further effort is required to determine the potential role of TRPM7 current in cardiac cellular biology and electrophysiology. Previous studies reported that oxidative stress, membrane stretch, and shear stress could activate TRPM7 [1, 40, 41], which may imply a potential role of TRPM7 in myocardial pathological process. A recent study has reported that TRPM7 channel gene expression is remarkably increased in fibroblasts isolated from human atria of patients with atrial fibrillation, it is, therefore, believed that TRPM7-mediated  $\text{Ca}^{2+}$  signals may mediate fibrogenesis in human atrial fibrillation [13].

In addition, abnormal  $\text{Ca}^{2+}$  signaling has been demonstrated to play an important role in atrial fibrillation pathophysiology [7, 12, 34, 45, 49]. A recent study in human atrial myocytes from atrial fibrillation patients clearly showed that  $\text{Ca}^{2+}$  handling changes are involved in atrial arrhythmogenesis, and delayed afterdepolarization-mediated triggered activity is more frequent in atrial myocytes from patients with atrial fibrillation [48]. It is believed that  $\text{Ca}^{2+}$ -related functions in electrical and structural remodeling processes participate in leading to the atrial fibrillation substrate [37]. Therefore, enhanced TRPM7 channels may also participate in the higher propensity to delayed afterdepolarization-mediated ectopic activity in patients with chronic atrial fibrillation. The identification of new molecular targets is important for improving drug therapy and discovery of biomarkers for risk stratification, and is a major goal in the management of atrial arrhythmias [11].

In summary, the present study has demonstrated for the first time that in addition to  $\text{Ca}^{2+}$  TRPM4 current, TRPM7 current is present in human atrial myocytes. TRPM7, but not TRPM4, is upregulated in atria of individuals with atrial fibrillation. More effort is required to clarify whether and how TRPM7 channels in atrial myocytes mediate the initiation and/or maintenance of atrial fibrillation.

**Acknowledgments** This study was supported by a small project grant (201109176057) from University of Hong Kong and a General Research Fund (770108 M) from Research Grant Council of Hong Kong. Yan-Hui Zhang was supported by a postgraduate scholarship from University of Hong Kong.

**Conflict of interest** None declared.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

## References

1. Aarts M, Iihara K, Wei WL, Xiong ZG, Arundine M, Cerwinski W, MacDonald JF, Tymianski M (2003) A key role for TRPM7 channels in anoxic neuronal death. *Cell* 115:863–877 (S0092867403010171)
2. Abbott BJ, Fukuda DS, Dorman DE, Occolowitz JL, Debono M, Farhner L (1979) Microbial transformation of A23187, a divalent cation ionophore antibiotic. *Antimicrob Agents Chemother* 16:808–812
3. Alexander SP, Mathie A, Peters JA (2007) Guide to receptors and channels (GRAC), 2nd edition (2007 Revision). *Br J Pharmacol* 150(Suppl 1):S1–S168. doi:10.1038/sj.bjp.0707199
4. Bush EW, Hood DB, Papst PJ, Chapo JA, Minobe W, Bristow MR, Olson EN, McKinsey TA (2006) Canonical transient receptor potential channels promote cardiomyocyte hypertrophy through activation of calcineurin signaling. *J Biol Chem* 281:33487–33496. doi:10.1074/jbc.M605536200

5. Castillo B, Porzgen P, Penner R, Horgen FD, Fleig A (2010) Development and optimization of a high-throughput bioassay for TRPM7 ion channel inhibitors. *J Biomol Screen* 15:498–507. doi: [10.1177/1087057110368294](https://doi.org/10.1177/1087057110368294)
6. Chauvet V, Qian F, Boute N, Cai Y, Phakdeekitacharoen B, Onuchic LF, Attie-Bitach T, Guicharnaud L, Devuyst O, Germino GG, Gubler MC (2002) Expression of PKD1 and PKD2 transcripts and proteins in human embryo and during normal kidney development. *Am J Pathol* 160:973–983. doi: [10.1016/S0002-9440\(10\)64919-X](https://doi.org/10.1016/S0002-9440(10)64919-X)
7. Chen WJ, Yeh YH, Lin KH, Chang GJ, Kuo CT (2011) Molecular characterization of thyroid hormone-inhibited atrial L-type calcium channel expression: implication for atrial fibrillation in hyperthyroidism. *Basic Res Cardiol* 106:163–174. doi: [10.1007/s00395-010-0149-5](https://doi.org/10.1007/s00395-010-0149-5)
8. Clapham DE (2007) SnapShot: mammalian TRP channels. *Cell* 129:220. doi: [10.1016/j.cell.2007.03.034](https://doi.org/10.1016/j.cell.2007.03.034)
9. Clapham DE (2003) TRP channels as cellular sensors. *Nature* 426:517–524. doi: [10.1038/nature02196](https://doi.org/10.1038/nature02196)
10. Demion M, Bois P, Launay P, Guinamard R (2007) TRPM4, a Ca<sup>2+</sup>-activated nonselective cation channel in mouse sino-atrial node cells. *Cardiovasc Res* 73:531–538. doi: [10.1016/j.cardiores.2006.11.023](https://doi.org/10.1016/j.cardiores.2006.11.023)
11. Dobrev D, Carlsson L, Nattel S (2012) Novel molecular targets for atrial fibrillation therapy. *Nat Rev Drug Discov* 11:275–291. doi: [10.1038/nrd3682](https://doi.org/10.1038/nrd3682)
12. Dobrev D, Nattel S (2011) New insights into the molecular basis of atrial fibrillation: mechanistic and therapeutic implications. *Cardiovasc Res* 89:689–691. doi: [10.1093/cvr/cvr021](https://doi.org/10.1093/cvr/cvr021)
13. Du J, Xie J, Zhang Z, Tsujikawa H, Fusco D, Silverman D, Liang B, Yue L (2010) TRPM7-mediated Ca<sup>2+</sup> signals confer fibrogenesis in human atrial fibrillation. *Circ Res* 106:992–1003. doi: [10.1161/CIRCRESAHA.109.206771](https://doi.org/10.1161/CIRCRESAHA.109.206771)
14. Gaborit N, Steenman M, Lamirault G, Le Meur N, Le Bouter S, Lande G, Leger J, Charpentier F, Christ T, Dobrev D, Escande D, Nattel S, Demolombe S (2005) Human atrial ion channel and transporter subunit gene-expression remodeling associated with valvular heart disease and atrial fibrillation. *Circulation* 112:471–481. doi: [10.1161/CIRCULATIONAHA.104.506857](https://doi.org/10.1161/CIRCULATIONAHA.104.506857)
15. Guinamard R, Chatelier A, Demion M, Potreau D, Patri S, Rahmati M, Bois P (2004) Functional characterization of a Ca(2+)-activated non-selective cation channel in human atrial cardiomyocytes. *J Physiol* 558:75–83. doi: [10.1113/jphysiol.2004.063974](https://doi.org/10.1113/jphysiol.2004.063974)
16. Guinamard R, Demion M, Chatelier A, Bois P (2006) Calcium-activated nonselective cation channels in mammalian cardiomyocytes. *Trends Cardiovasc Med* 16:245–250. doi: [10.1016/j.tcm.2006.04.007](https://doi.org/10.1016/j.tcm.2006.04.007)
17. Guinamard R, Demion M, Magaud C, Potreau D, Bois P (2006) Functional expression of the TRPM4 cationic current in ventricular cardiomyocytes from spontaneously hypertensive rats. *Hypertension* 48:587–594. doi: [10.1161/01.HYP.0000237864.65019.a5](https://doi.org/10.1161/01.HYP.0000237864.65019.a5)
18. Gwanyanya A, Amuzescu B, Zakharov SI, Macianskiene R, Sipido KR, Bolotina VM, Vereecke J, Mubagwa K (2004) Magnesium-inhibited, TRPM6/7-like channel in cardiac myocytes: permeation of divalent cations and pH-mediated regulation. *J Physiol* 559:761–776. doi: [10.1113/jphysiol.2004.067637](https://doi.org/10.1113/jphysiol.2004.067637)
19. Gwanyanya A, Sipido KR, Vereecke J, Mubagwa K (2006) ATP and PIP2 dependence of the magnesium-inhibited, TRPM7-like cation channel in cardiac myocytes. *Am J Physiol Cell Physiol* 291:C627–C635. doi: [10.1152/ajpcell.00074.2006](https://doi.org/10.1152/ajpcell.00074.2006)
20. Harada M, Ledoux J, Qi XY, Maguy A, Ordog B, Murohara T, Kamiya K, Kodama I, Schotten U, Van Wagoner D, Dobrev D, Nattel S (2011) TRPC3 channels regulate cardiac fibroblast proliferation by controlling calcium entry. *Heart Rhythm* 8:S251
21. Harteneck C (2005) Function and pharmacology of TRPM cation channels. *Naunyn Schmiedebergs Arch Pharmacol* 371:307–314. doi: [10.1007/s00210-005-1034-x](https://doi.org/10.1007/s00210-005-1034-x)
22. He ML, Liu WJ, Sun HY, Wu W, Liu J, Tse HF, Lau CP, Li GR (2011) Effects of ion channels on proliferation in cultured human cardiac fibroblasts. *J Mol Cell Cardiol* 51:198–206. doi: [10.1016/j.yjmcc.2011.05.008](https://doi.org/10.1016/j.yjmcc.2011.05.008)
23. Inoue R, Jensen LJ, Shi J, Morita H, Nishida M, Honda A, Ito Y (2006) Transient receptor potential channels in cardiovascular function and disease. *Circ Res* 99:119–131. doi: [10.1161/01.RES.0000233356.10630.8a](https://doi.org/10.1161/01.RES.0000233356.10630.8a)
24. Inoue R, Jian Z, Kawarabayashi Y (2009) Mechanosensitive TRP channels in cardiovascular pathophysiology. *Pharmacol Ther* 123:371–385. doi: [10.1016/j.pharmthera.2009.05.009](https://doi.org/10.1016/j.pharmthera.2009.05.009)
25. Jiang J, Li M, Yue L (2005) Potentiation of TRPM7 inward currents by protons. *J Gen Physiol* 126:137–150. doi: [10.1085/jgp.200409185](https://doi.org/10.1085/jgp.200409185)
26. Ju YK, Chu Y, Chaulet H, Lai D, Gervasio OL, Graham RM, Cannell MB, Allen DG (2007) Store-operated Ca<sup>2+</sup> influx and expression of TRPC genes in mouse sinoatrial node. *Circ Res* 100:1605–1614. doi: [10.1161/CIRCRESAHA.107.152181](https://doi.org/10.1161/CIRCRESAHA.107.152181)
27. Kuwahara K, Wang Y, McAnally J, Richardson JA, Bassel-Duby R, Hill JA, Olson EN (2006) TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. *J Clin Invest* 116:3114–3126. doi: [10.1172/JCI27702](https://doi.org/10.1172/JCI27702)
28. Li GR, Feng J, Wang Z, Fermi B, Nattel S (1995) Comparative mechanisms of 4-aminopyridine-resistant Ito in human and rabbit atrial myocytes. *Am J Physiol* 269:H463–H472
29. Li GR, Feng J, Wang Z, Nattel S (1996) Transmembrane chloride currents in human atrial myocytes. *Am J Physiol* 270:C500–C507
30. Li GR, Sun H, Deng X, Lau CP (2005) Characterization of ionic currents in human mesenchymal stem cells from bone marrow. *Stem Cells* 23:371–382. doi: [10.1634/stemcells.2004-0213](https://doi.org/10.1634/stemcells.2004-0213)
31. Li GR, Sun HY, Zhang XH, Cheng LC, Chiu SW, Tse HF, Lau CP (2009) Omega-3 polyunsaturated fatty acids inhibit transient outward and ultra-rapid delayed rectifier K<sup>+</sup> currents and Na<sup>+</sup> current in human atrial myocytes. *Cardiovasc Res* 81:286–293. doi: [10.1093/cvr/cvn322](https://doi.org/10.1093/cvr/cvn322)
32. Li GR, Wang HB, Qin GW, Jin MW, Tang Q, Sun HY, Du XL, Deng XL, Zhang XH, Chen JB, Chen L, Xu XH, Cheng LC, Chiu SW, Tse HF, Vanhoutte PM, Lau CP (2008) Acacetin, a natural flavone, selectively inhibits human atrial repolarization potassium currents and prevents atrial fibrillation in dogs. *Circulation* 117:2449–2457. doi: [10.1161/CIRCULATIONAHA.108.769554](https://doi.org/10.1161/CIRCULATIONAHA.108.769554)
33. Li M, Jiang J, Yue L (2006) Functional characterization of homo- and heteromeric channel kinases TRPM6 and TRPM7. *J Gen Physiol* 127:525–537. doi: [10.1085/jgp.200609502](https://doi.org/10.1085/jgp.200609502)
34. Lugenbiel P, Thomas D, Kelemen K, Trappe K, Bikou O, Schweizer PA, Voss F, Becker R, Katus HA, Bauer A (2012) Genetic suppression of Galphas protein provides rate control in atrial fibrillation. *Basic Res Cardiol* 107:265. doi: [10.1007/s00395-012-0265-5](https://doi.org/10.1007/s00395-012-0265-5)
35. Morita H, Honda A, Inoue R, Ito Y, Abe K, Nelson MT, Brayden JE (2007) Membrane stretch-induced activation of a TRPM4-like nonselective cation channel in cerebral artery myocytes. *J Pharmacol Sci* 103:417–426. doi: [10.1002/jps.11332](https://doi.org/10.1002/jps.11332)
36. Nadler MJ, Hermosura MC, Inabe K, Perraud AL, Zhu Q, Stokes AJ, Kurosaki T, Kinet JP, Penner R, Scharenberg AM, Fleig A (2001) LTRPC7 is a Mg-ATP-regulated divalent cation channel required for cell viability. *Nature* 411:590–595. doi: [10.1038/35079092](https://doi.org/10.1038/35079092)
37. Nattel S, Dobrev D (2012) The multidimensional role of calcium in atrial fibrillation pathophysiology: mechanistic insights and therapeutic opportunities. *Eur Heart J*. doi: [10.1093/eurheartj/ehs079](https://doi.org/10.1093/eurheartj/ehs079)

38. Nilius B (2007) TRP channels in disease. *Biochim Biophys Acta* 1772:805–812. doi:[10.1016/j.bbadis.2007.02.002](https://doi.org/10.1016/j.bbadis.2007.02.002)
39. Nilius B, Mahieu F, Prenen J, Janssens A, Owsianik G, Vennekens R, Voets T (2006) The Ca<sup>2+</sup>-activated cation channel TRPM4 is regulated by phosphatidylinositol 4,5-bisphosphate. *EMBO J* 25:467–478. doi:[10.1038/sj.emboj.7600963](https://doi.org/10.1038/sj.emboj.7600963)
40. Numata T, Shimizu T, Okada Y (2007) TRPM7 is a stretch- and swelling-activated cation channel involved in volume regulation in human epithelial cells. *Am J Physiol Cell Physiol* 292:C460–C467. doi:[10.1152/ajpcell.00367.2006](https://doi.org/10.1152/ajpcell.00367.2006)
41. Oancea E, Wolfe JT, Clapham DE (2006) Functional TRPM7 channels accumulate at the plasma membrane in response to fluid flow. *Circ Res* 98:245–253. doi:[10.1161/01.RES.0000200179.29375.cc](https://doi.org/10.1161/01.RES.0000200179.29375.cc)
42. Ohba T, Watanabe H, Murakami M, Takahashi Y, Iino K, Kurumitsu S, Mori Y, Ono K, Iijima T, Ito H (2007) Upregulation of TRPC1 in the development of cardiac hypertrophy. *J Mol Cell Cardiol* 42:498–507. doi:[10.1016/j.yjmcc.2006.10.020](https://doi.org/10.1016/j.yjmcc.2006.10.020)
43. Runnels LW, Yue L, Clapham DE (2001) TRP-PLIK, a bifunctional protein with kinase and ion channel activities. *Science* 291:1043–1047. doi:[10.1126/science.1058519](https://doi.org/10.1126/science.1058519)
44. Runnels LW, Yue L, Clapham DE (2002) The TRPM7 channel is inactivated by PIP(2) hydrolysis. *Nat Cell Biol* 4:329–336. doi:[10.1038/ncb781](https://doi.org/10.1038/ncb781)
45. Suenari K, Chen YC, Kao YH, Cheng CC, Lin YK, Chen YJ, Chen SA (2011) Discrepant electrophysiological characteristics and calcium homeostasis of left atrial anterior and posterior myocytes. *Basic Res Cardiol* 106:65–74. doi:[10.1007/s00395-010-0132-1](https://doi.org/10.1007/s00395-010-0132-1)
46. Tao R, Lau CP, Tse HF, Li GR (2007) Functional ion channels in mouse bone marrow mesenchymal stem cells. *Am J Physiol Cell Physiol* 293:C1561–C1567. doi:[10.1152/ajpcell.00240.2007](https://doi.org/10.1152/ajpcell.00240.2007)
47. Van Wagoner DR, Voigt N, Bunnell B, Barnard J, Schotten U, Nattel S, Ravens U, Dobrev D (2009) Transient receptor potential canonical (TRPC) channel subunit remodeling in clinical and experimental AF. *Heart Rhythm* 6:PO06-77
48. Voigt N, Li N, Wang Q, Wang W, Trafford AW, Abu-Taha I, Sun Q, Wieland T, Ravens U, Nattel S, Wehrens XH, Dobrev D (2012) Enhanced sarcoplasmic reticulum Ca<sup>2+</sup> leak and increased Na<sup>+</sup>-Ca<sup>2+</sup> exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. *Circulation* 125:2059–2070. doi:[10.1161/CIRCULATIONAHA.111.067306](https://doi.org/10.1161/CIRCULATIONAHA.111.067306)
49. Wakili R, Voigt N, Kaab S, Dobrev D, Nattel S (2011) Recent advances in the molecular pathophysiology of atrial fibrillation. *J Clin Invest* 121:2955–2968. doi:[10.1172/JCI46315](https://doi.org/10.1172/JCI46315)
50. Watanabe H, Murakami M, Ohba T, Takahashi Y, Ito H (2008) TRP channel and cardiovascular disease. *Pharmacol Ther* 118:337–351. doi:[10.1016/j.pharmthera.2008.03.008](https://doi.org/10.1016/j.pharmthera.2008.03.008)